Effectiveness of a 23-valent pneumococcal polysaccharide vaccine for the prevention of pneumococcal pneumonia in the elderly with chronic respiratory diseases: a case-control study of a single center

被引：4
|
作者：
Masuda, Toshihiro [1 ]
Nakatani, Eiji [2 ,3 ]
Shirai, Toshihiro [1 ]
Akamatsu, Taisuke [1 ]
Tamura, Kanami [1 ]
Takahashi, Shingo [1 ]
Tanaka, Yuko [1 ]
Watanabe, Hirofumi [1 ]
Endo, Yoshinari [1 ]
Suzuki, Takahito [1 ]
Saigusa, Mika [1 ]
Yamamoto, Akito [1 ]
Morita, Satoru [1 ]
Sato, Yoko [2 ]
Asada, Kazuhiro [1 ]
机构：
[1] Shizuoka Prefectural Gen Hosp, Dept Resp Med, Shizuoka, Japan
[2] Shizuoka Prefectural Gen Hosp, Res Support Ctr, Div Clin Biostat, 4-27-1 Kita Ando, Shizuoka 4208527, Japan
[3] Shizuoka Grad Univ Publ Hlth, Grad Sch Publ Hlth, Aoi Ku, 4-27-2 Kitaando, Shizuoka 4200881, Japan
来源：
BMC PULMONARY MEDICINE | 2021年 / 21卷 / 01期
关键词：
Chronic respiratory disease; Elderly; Pneumococcal polysaccharide vaccine; Pneumococcus; Pneumonia; Vaccine;
D O I：
10.1186/s12890-021-01491-w
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Background The effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in preventing pneumococcal pneumonia has been controversial. Methods To evaluate the effectiveness of the PPSV23 in elderly outpatients with chronic respiratory diseases, we carried out a case-control study, including 4128 outpatients aged >= 65 years, in the respiratory department. Results There were 320 vaccinated patients, of which 164 were diagnosed with pneumococcal pneumonia. The adjusted odds ratio was 0.39 (95% confidence interval (CI), 0.17 to 0.89). In the subsets consisting of age groups >= 70 and >= 75 years, the adjusted odds ratio (95% CI) was respectively 0.16 (0.04 to 0.67) and 0.15 (0.02 to 1.12). Conclusion This real-world study suggests that PPSV23 can be useful in preventing pneumococcal pneumonia in the elderly with chronic respiratory diseases.
引用
收藏
页数：6
相关论文
共 50 条
  • [31] Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses
    Kawakami, Kenji
    Kishino, Hiroyuki
    Kanazu, Shinichi
    Toshimizu, Nobuhito
    Takahashi, Kenichi
    Sterling, Tina
    Wang, Meihua
    Musey, Luwy
    VACCINE, 2016, 34 (33) : 3875 - 3881
  • [32] Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia
    Lindstrom, Vesa
    Aittoniemi, Janne
    Salmenniemi, Urpu
    Kayhty, Helena
    Huhtala, Heini
    Sinisalo, Marjatta
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (12) : 2910 - 2913
  • [33] Eight years of active proposal of pneumococcal 23-valent polysaccharide vaccine: Survey on coverage rate among elderly and chronic patients
    Martinelli, Domenico
    Tafuri, Silvio
    Caputi, Giovanni
    Fortunato, Francesca
    Reggio, Paolo
    Germinario, Cinzia
    Prato, Rosa
    AMERICAN JOURNAL OF INFECTION CONTROL, 2010, 38 (04) : E8 - E15
  • [34] A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine
    C. R. Laratta
    K. Williams
    D. Vethanayagam
    M. Ulanova
    H. Vliagoftis
    Allergy, Asthma & Clinical Immunology, 13
  • [35] A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine
    Laratta, C. R.
    Williams, K.
    Vethanayagam, D.
    Ulanova, M.
    Vliagoftis, H.
    ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2017, 13
  • [36] Cost-Effectiveness Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Program for the Elderly Aged 60 Years or Older in Shanghai, China
    Sun, Xiaodong
    Tang, Yuekun
    Ma, Xiaoying
    Guo, Xiang
    Huang, Zhuoying
    Ren, Jia
    Qiu, Jing
    Jiang, Hongli
    Lu, Yihan
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [37] The Effectiveness of 23-valent Pneumococcal Polysaccharide Vaccine on Elderly Colorectal Cancer Long-Term Survivors: A population-based exact-matched cohort study
    Lee, Moon-Sing
    Chiou, Shin-Yi
    Hsu, Feng-Chun
    Lin, Hon-Yi
    Li, Chung-Yi
    Hung, Shih-Kai
    Yu, Ben-Hui
    Wu, Chin-Chia
    Chen, Liang-Cheng
    Chew, Chia-Hui
    Chiou, Wen-Yen
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [38] Failure to vaccinate or failure of vaccine? Effectiveness of the 23-valent pneumococcal polysaccharide vaccine program in Indigenous adults in the Northern Territory of Australia
    Moberley, S.
    Krause, V.
    Cook, H.
    Mulholland, K.
    Carapetis, J.
    Torzillo, P.
    Andrews, R.
    VACCINE, 2010, 28 (11) : 2296 - 2301
  • [39] Combined 13-valent pneumococcal conjugate and 23-valent pneumococcal polysaccharide vaccine regimens for adults with systemic lupus erythematosus: Does the sequence of pneumococcal vaccination affect immunogenicity responses? A single-center cohort study in Brazil
    de Rezende, Rodrigo Poubel Vieira
    Oliveira-Santos, Marise
    Andrade, Luis Eduardo Coelho
    Klumb, Evandro Mendes
    LUPUS, 2023, 32 (05) : 694 - 703
  • [40] The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales
    Melegaro, A
    Edmunds, WJ
    EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2004, 19 (04) : 365 - 375
12345